ID   OCI-My3
AC   CVCL_E336
SY   OCI-MY3; OCI-My 3; OCIMy3
DR   Wikidata; Q54931786
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=1912582;
RX   PubMed=8138440;
RX   PubMed=10936422;
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Doubling time: 32 hours (PubMed=1912582).
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 21-03-23; Version: 10
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   PubMed=1912582; DOI=10.1182/blood.V78.8.1996.1996;
RA   Hitzler J.K., Martinez-Valdez H., Bergsagel D.E., Minden M.D.,
RA   Messner H.A.;
RT   "Role of interleukin-6 in the proliferation of human multiple myeloma
RT   cell lines OCI-My 1 to 7 established from patients with advanced stage
RT   of the disease.";
RL   Blood 78:1996-2004(1991).
//
RX   PubMed=8138440; DOI=10.1016/0360-3016(94)90107-4;
RA   Gluck S., Van Dyk J., Messner H.A.;
RT   "Radiosensitivity of human clonogenic myeloma cells and normal bone
RT   marrow precursors: effect of different dose rates and fractionation.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 28:877-882(1994).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//